2016). The schizophrenia associated BRD1 gene regulates behavior, neurotransmission, and expression of schizophrenia risk enriched gene sets in mice. Biological psychiatry. The schizophrenia associated BRD1 gene regulates behavior, neurotransmission, and expression of schizophrenia risk enriched gene sets in miceBRD1 in schizophrenia, behavior, and neurobiology, Biological Psychiatry, http://dx.
Key words: BRD1, knockout mouse, schizophrenia, behavior, electrophysiology, RNAseq, monoaminergic neurotransmission, cyclic AMP response element-binding protein (CREB),
DARPP32 signaling

Introduction
Schizophrenia is a common and severe mental disorder. It is highly heritable with a notably polygenic genetic architecture comprising thousands of risk variants (1; 2) . The distal part of chromosome 22q has long been implicated with schizophrenia (3; 4) and a susceptibility locus at 22q13.3 has been identified in the isolated population of the Faroe Islands (5) . The BRD1 gene, which is located within this locus, has repeatedly been associated with schizophrenia in large Caucasian case-control samples (6; 7) and the BRD1 promoter SNP rs138880 was recently identified as the most significantly associated variant in a large schizophrenia GWAS meta-analysis (11, 185 cases and 10,768 controls) and family-based replication study (6, 298 individuals including 3,286 cases) (8) . Although the BRD1 locus falls short of genome-wide significance in the Psychiatric Genomics Consortium (PGC) schizophrenia mega-GWASs using traditional statistical methods (p=4.38E-05 in PGC1 (1) and p=3.31E-07 in PGC2 (2)), the locus is found genome-wide significant and predicted to be highly replicable when applying an Empirical Bayes statistical approach already in the PGC1 dataset (9) .
BRD1 encodes the bromodomain-containing protein 1 (BRD1) which has been identified in complexes possessing acetyltransferase activity towards histone H3 (10)in particular H3K14 (11) . In cell lines, BRD1 is found attached to genomic regions, primarily close to transcription start sites, and it has been demonstrated to influence the expression of large gene sets (11; 12) . Pointing to an involvement of BRD1 as a regulatory hub gene in brain development and susceptibility to mental illness, the BRD1 chromatin interactome is significantly enriched for schizophrenia riskand in particular with genes acting in signaling pathways important during neurodevelopment (12) .
In line with this, BRD1 is essential during embryogenesis as inactivation of both alleles of Brd1 in mice leads to compromised eye development, neural tube closure, and a lethal maturation defect in embryonic hematopoiesis (11) . Although its cortical expression level peaks during intrauterine development (13) , BRD1 remains widely and abundantly expressed in the adult mammalian central nervous system (6; 14) and a role in the postnatal brain has been indicated by its differential regulation in various brain regions in rats upon both electroconvulsive seizures (15) and chronic restraint stress (16). Combined, current data suggest that BRD1 is important for both pre-and postnatal transcriptional regulation in the brain and could contribute to schizophrenia etiopathology by influencing histone modification and thereby the chromatin state around multiple schizophrenia risk genes.
In the present study, we show that human BRD1 promoter risk alleles correlate with reduced BRD1 mRNA and reduced transcriptional drive. We demonstrate that genetically engineered mice (Brd1 +/mice) with reduced Brd1 expression and cerebral H3K14 hypoacetylation recapitulate key features of schizophrenia symptomatology and neurochemistry. Through a range of molecular, cellular, and bioinformatic investigations, including transcriptome profiling of selected brain regions, we provide novel insight into the biological changes that underlie the phenotypes and suggest links relevant to schizophrenia etiopathology. 
Methods and Materials
Dual luciferase assay of BRD1 promoter fragments
Genomic DNA from two in-house control subjects homozygous for the A or C allele of the rs138880 SNP was used as templates to PCR amplify a 1031 bp region of the promoter potentially driving the transcription of the short exon 7 variant of BRD1. Both subjects provided written, informed consent for participation, and approval was obtained from local ethics committees. See
Supplemental Methods and Materials for details.
Animals
A mouse line heterozygous for a targeted deletion within the Brd1 gene, Brd1 tm1569.2Arte (Brd1 +/− ) was generated by TaconicArtemis GmbH (Cologne, Germany) using a targeting vector (pBrd1 
Behavioral phenotyping
Detailed description of social interaction, three-chamber sociability and preference for novelty test, spontaneous alternation, continuous alternation, and contextual fear conditioning, associative memory retrieval, prepulse inhibition (PPI), spontaneous-and drug-induced hyperactivity, PTZinduced seizures and drugs used in testing can all be found in Supplemental Methods and
Materials.
Quantification of neurotransmitters
Mice were sacrificed by cervical dislocation and striatal tissue was collected by free-hand dissection and processed for HPLC analyses. For details on HPLC protocols, see Supplemental Methods and Materials.
Brain slice electrophysiology
Whole-cell patch-clamp recordings of GABA A -receptor-mediated currents were performed in acute coronal brain slices of 7-8 weeks old male mice (number of mice (n) in Tables S5). For details see
Supplemental Methods and Materials.
RNAseq analysis on tissue micropunches
Briefly, brains from adolescent mice were snap frozen in 2-methylbutane and sectioned (1 mm) coronally at -20°C. aCC and striatum (caudate nucleus) were identified (18) and punched by a needle (1 mm diameter). RNAseq experiments and analyses were performed as previously described (19) . For details and validation of DEGs, see Supplemental Methods and Materials.
Immunohistochemistry and stereology
Brains from 8 weeks old formaldehyde perfused mice were moulded in Tissue-Tek ® (Sakura, Tokyo, Japan). 40 μm coronal sections containing aCC (Bregma 1.5 mm. to 0.5 mm.) were cut at -20°C using a MICROM HM355 cryostat and immunohistochemically stained with an antibody directed against Parvalbumin (Pvalb). For more details and description of stereological measures see Supplemental Methods and Materials.
Enrichment analysis of DEGs
Gene set analysis was performed with MAGMA (20) using default settings, based on summary statistics from the PGC2 schizophrenia GWAS (2) and other publicly available GWASs while excluding the MHC region and imputed SNPs with info score < 0.8. The gene annotation files consisted of lists of genes detected in aCC, striatum, and the two regions combined. See
Supplemental Methods and Materials for details.
Analysis of overlap between DEGs and genes located in schizophrenia GWAS risk loci
The significance of overlap between the set of DEGs and genes in schizophrenia GWAS risk loci, as defined by others (2), was analyzed using permutation analysis based on the combined transcripts detected in striatum and in aCC (n=42,198) for which human homologous genes exist (n=20,958).
In each permutation a gene set was sampled with the same number of genes as the DEG set, and containing genes of similar sizes as the genes in the DEG set. The p value of the significance of the overlap was estimated as the number of permuted gene sets that contained equally many or more genes present in schizophrenia GWAS loci as the set of nominally significant DEGs, divided by the total number of permutations. 
Results
Correlation between BRD1 risk alleles and BRD1 expression
Due to the location of the rs138880 SNP in a putative BRD1 promoter binding site for transcriptional repressor HES1 (6), we assessed the association between the SNP and BRD1 expression in a cis-eQTL analysis using a publically available dataset with expression phenotypes of B lymphoblastoid cell lines established from HapMap3 individuals (21). We found that carriers of the rs138880 risk allele (C allele) expressed significantly less BRD1 mRNA than non-carriers among individuals of European ancestry (Figure 1A , p<0.05 and Table S1 ). SNPs in high LD with rs138880 were likewise correlated with BRD1 mRNA levels, including all reported SNPs in BRD1 that have shown association with schizophrenia (6-8; 22) ( Figure S1 and Table S1 ). The same effect was seen for SNPs in the haploblock in a larger blood eQTL dataset (5,311 individuals, p=9.0E-07, Z-score =-5.2 for the most significant SNP) (17) and similarly in a relatively small brain eQTL dataset for a SNP (rs7410537) in strong LD with rs138880 ( Figure 1B , 112 individuals, p=0.08) (13) whereas no significant BRD1 cis-eQTLs were found in the GTEx database (23).
To investigate whether particularly the rs138880 alleles have different transcriptional drive, we cloned the promoter region harboring either the A or C allele of rs138880 (and otherwise being 100% identical) into a luciferase reporter vector ( Figure 1C) . Four independent transfections of these vectors into mouse neuroblastoma Neuro2A cells (with co-transfection of a pRL-TK vector for normalization) revealed that transcriptional drive was significantly lower for the fragment containing the risk C allele (Figure 1C and Figure S2 ).
Generation and basic characterization of heterozygous Brd1 +/− mice
In order to examine the behavioral and underlying neurophysiological and molecular consequences of reduced Brd1 expression, we generated a strain of heterozygous Brd1 tm1569.2Arte (Brd1 +/− ) mice carrying a deletion of exon 3-5 of the Brd1 gene ( Figure 1D and Figure S3A ). The deletion is expected to target all annotated transcript variants of the gene by introducing a premature stop codon in exon 6. Brd1 mRNA expression was reduced to approximately 50% in Brd1 +/mice compared to wild type (WT) mice in all tissues examined (Figure 1E In line with BRD1's role as a transcriptional regulator in the brain and in accordance with what has previously been reported in erythroblasts derived from BRD1 depleted mice (11), we found that global cerebral H3K14 acetylation was reduced by ~19% in male Brd1 +/mice (Figure 1G, p<0.05).
Behavioral assessment of heterozygous Brd1 +/− mice
Given the genetic association of BRD1 with schizophrenia and the enrichment of schizophrenia risk genes in its chromatin interactome, we assessed the performance of Brd1 +/male mice in a comprehensive panel of behavioral tasks ( Table 1 ) designed to evaluate whether reduced Brd1 expression elicits behavioral changes with translational relevance to schizophrenia symptomatology (24-27) -either at baseline or in response to psychotomimetic drugs.
Social behavior, cognition and information processing
To investigate behaviors with face validity to negative symptoms in schizophrenia, we observed the social behavior of Brd1 +/mice in a test for direct social interaction. Brd1 +/mice did not differ from WT littermates on total time spent investigating an unfamiliar mouse of same genotype (Figure   2A ). However, they spent less time engaged in passive interactions (Figure 2A , p<0.05), aggressive behavior was almost exclusively displayed by Brd1 +/mice (Figure 2A, p<0 .05), and they showed a significant increase in latency to first social interaction (Figure 2B, p<0.01) .
In a test for sociability and preference for social novelty, Brd1 +/mice lacked the preference for social stimuli in the form of prioritized exploration of a real mouse over a toy mouse (Figure 2C, p<0.001). They, however, acknowledged formerly introduced mice by displaying preferential exploration of novel mice over familiar mice to the same degree as did WT mice ( Figure 2D) . In an extension of this test, we exposed target mice to the same "novel" mouse (now familiar) and a new novel mouse a week after the first test to assess long-term social recognition memory. In this setting, Brd1 +/mice displayed significantly less preference investigating the new novel mice compared to WT mice (Figure 2E , p<0.05).
In the fear conditioning test for associative learning and contextual long term memory, levels of pre-training (basal) freezing did not differ between genotypes ( Figure 2F ). However, Brd1 +/mice spent significantly less time freezing compared to WT mice during the acquisition phase ( Figure   2F , genotype effect, F 1,20 =8.142, p<0.01) and following post-acquisition recording (Figure 2F, p<0.05), whereas motor activity did not differ between the groups (Figure S5J ). Supportive of a deficit in long term memory, as indicated in the test for social recognition memory, Brd1 +/mice displayed less time freezing than WT mice when re-introduced to the context box 3 days after acquisition (Figure 2G , p<0.01), more prominently 7 days after acquisition (Figure 2G Sensorimotor gating, as measured by prepulse inhibition of the acoustic startle response (PPI), is commonly decreased in individuals with schizophrenia indicating an impaired pre-attentive information processing (28; 29). This can be readily assessed in rodents (30; 31) with or without the administration of psychotomimetics (32) .
Baseline PPI response was similar in Brd1 +/and WT mice ( Figure S5N Cocaine caused a left-shift in the activity profile at the highest dose (30 mg/kg) with Brd1 +/mice reaching peak activity earlier than WT mice (Figure 3C , genotype x time interaction effect, F 23,506 =2.043, p<0.01) but did not result in increased horizontal activity in Brd1 +/mice ( Figure 3D ).
Additionally, Brd1 +/mice responded to even a low dose of cocaine (10 mg/kg) with a significant increase in rearing activity compared to WT mice (Figure 3E , p<0.05). Treatment with amphetamine did not result in any significant differences in activity between genotypes ( Figure   S6 ).
The observed psychotomimetic drug sensitivity in Brd1 +/mice points to changes in several striatal neurotransmitter systems -including striatal monoamine neurotransmission, which has traditionally been seen as a key pathological process in schizophrenia (34; 35) . Accordingly, we measured total striatal dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and serotonin (5-HT) levels in tissue extracts and found a significant increase in both DA and 5-HT in Due to the putative role of BRD1 as a transcriptional regulator during neurodevelopment and in the adult brain, we performed genome-wide transcriptome profiling of tissue micro-punches obtained from the dorsal striatum using RNAseq to assess transcriptomic differences between Brd1 +/and WT mice. This analysis revealed 1378 nominally significant differentially expressed genes (DEGs; 397 downregulated and 981 upregulated) of which 269 (37 downregulated and 232 upregulated) were significant after Benjamini-Hochberg false discovery rate (FDR) correction at 5% (Table S3) .
Ingenuity Pathway analysis (IPA) of the nominally significant DEGs revealed significant enrichment (p<0.05) of pathways including G-protein coupled receptor signaling, cAMP mediated signaling, Protein kinase A (PKA) signaling, Dopamine-DARPP-32 feedback in cAMP signaling, and CREB (cAMP Responsive Element Binding Protein) signaling as well as DA receptor, 5-HT receptor, glutamate receptor, and GABA receptor signaling among others (Table S4) . Remarkably, the entire annotated network of genes involved with 'Behavior, Hereditary disorder and Neurological disease' were represented among the DEGs (p<3E-30), including the typical antipsychotic drug target gene and schizophrenia risk gene (2) , Drd2, encoding the DA receptor D2 ( Figure S8 ). Using high throughput qPCR, we validated differential expression of 34 out of 50 randomly selected FDR significant DEGs in RNA samples extracted from tissue micro-punches from independent biological replicates, indicating approximately 70% positive predictive value in the performed analysis (Table S3 ). In support of altered striatal DA transmission, we specifically validated both decreased Drd2 mRNA (Table S3 ) and Drd2 protein levels in Brd1 +/mice ( Figure   3H , p<0.05).
Neuronal excitability and synaptic inhibition
As Brd1 +/mice showed increased sensitivity to PCP in tests of cognition and PPI, we speculated that imbalanced excitation-inhibition might be a general cerebral feature in Brd1 +/mice. To coarsely examine if cortical GABAergic inhibitory tone is affected in Brd1 +/mice, we administered mice with various doses of the GABA-A receptor antagonist, PTZ, and observed for seizure activity. Brd1 +/mice displayed increased propensity for myoclonic jerks at 70 mg/kg (Figure 4A In order to assess inhibition at the synaptic level, we performed whole-cell patch-clamp recordings of inhibitory postsynaptic currents from pyramidal neurons in layers 2/3 of the aCC in acute coronal brain slices. In the presence of kynurenic acid, an inhibitor of ionotropic glutamate receptors, we found a ~40% decrease in the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) in Brd1 +/compared to WT mice (Figure 4D-E and H, Table S5 , p<0.05). We repeated the experiments in the presence of the Na + channel blocker, tetrodotoxin (TTX), to isolate miniature IPSCs (mIPSCs) and found a ~38% decrease in their frequency (Figure 4F-G and I; Table S5 , p<0.01). There was no significant difference in sIPCSs or mIPSCs mean amplitudes (Figure 4J-K; Table S5 ) or time parameters between Brd1 +/and WT mice. Similar findings were made in pyramidal neurons of the somatosensory cortex (Table S5) , supporting a widespread cerebral
Cortical gene expression profiling and Pvalb immunohistochemistry
Addressing the molecular mechanisms underlying altered cortical inhibition in Brd1 +/mice, we performed transcriptional profiling on RNA extracted from aCC tissue micro-punches by RNAseq.
The analysis revealed 919 nominally significant DEGs (451 downregulated and 468 upregulated) of which 118 (61 down-regulated and 57 up-regulated) were significant after FDR correction at 5% (Table S6) . Although less convincing than for DEGs detected in striatum, by IPA pathway analyses nominally significant DEGs were found to cluster in several canonical pathways (p<0.05) (Table   S7 ), including TGF-β signaling, Dopamine-DARPP32 feedback in cAMP signaling, and in accordance with the observed increase in PCP sensitivity, Glutamate receptor signaling. In the latter, genes encoding ion channels (Grik3, Grik5, Grid2, Grin2b, and Grin2d), G-protein coupled receptors (Grm1 and Grm2), post-synaptic density protein (Dlg4), and vesicular glutamate transporter (Slc17a7) were upregulated whereas Homer1, encoding a post-synaptic density scaffolding protein, was down-regulated in Brd1 +/mice ( Figure S10) . In relation to altered inhibitory signaling in Brd1 +/mice, the marker for fast-spiking interneurons, Pvalb, was significantly downregulated by ~25% (Table S6 ). To assess whether this reduction in Pvalb mRNA was associated with a reduction in the number of Pvalb immunoreactive cells, we further estimated the number of this sub-class of interneurons in the aCC by immunohistochemistry coupled with stereological counting and found an overall ~28% reduction (Figure 4L, p<0.05 ).
Identification of DEG upstream regulators
Overall, nominally significant DEGs identified in aCC overlapped significantly with those identified in striatum (Table S6 , Chi 2 , p<0.001).
Supportive of a common regulatory mechanism underlying the transcriptomic changes seen in different brain regions, IPA upstream regulator analyses of the nominally significant DEGs identified in striatum and aCC, respectively, both pointed to CREB1, BDNF, and HTT as the most likely upstream regulators of the DEGs (Table S8 , p<1E-5 for all). Strikingly, this similarity in upstream regulators of the DEGs occurred despite a limited overlap in the specific DEGs identifying these regulators in the two brain regions investigated (Table S8 ). Since phosphorylation and thus activation of CREB is the downstream effect of GPCR-cAMP-DARPP-32 signaling (36) and DEGs from both striatum and aCC cluster in this pathway, we investigated Creb phosophorylation in whole-brain protein extracts. We found that Creb was hyper-phosphorylated in Brd1 +/mice compared to WT mice (Figure 5A, p<0 .05) and further, that its transcriptional target, c-Fos, was significantly more abundant (Figure 5A, p<0 .05).
Schizophrenia risk enrichment in DEG sets
Using summary statistics from the largest to date schizophrenia GWAS (2), we assessed risk enrichment by MAGMA (20) analysis of DEGs from both aCC and striatum -and the two regions combined. Interestingly, we found that DEGs from each brain region, separately, was enriched with schizophrenia risk (Figure S11, p<0 .05) and more significantly when the two regions were assessed collectively (Figure S11, p<0.01) . In a secondary exploratory analysis, we assessed whether DEGs were enriched for common variant risk in other disorders/traits. Besides from DEGs in aCC, which showed enrichment for bipolar disorder (Figure S11, p<0.05) , no risk enrichment was seen for other brain and non-brain disorders/traits (Figure S11) . In line with the identified schizophrenia risk enrichment, we found that a significant higher proportion of striatum and aCC DEGs localize to genome-wide significant schizophrenia risk loci than expected by chance (Table S9 , p<0.01), including loci containing e.g. the calcium channel subunits genes, Cacna1c and Cacnb2, the cholinergic muscarinic receptor 4 gene, Chrm4, Drd2, and the transcription factor 4 gene, Tcf4.
Noteworthy in this context, the 3'UTR of BRD1 contains a conserved target site for microRNA-137, which is also is located in a schizophrenia GWAS locus (37) .
Discussion
BRD1 is located in a 150 kb haploblock comprising the four genes ALG12, CRELD2, ZBED4, and BRD1. In addition to the genetic associations and the schizophrenia risk enrichment of BRD1's chromatin interactome reported previously (12) , the present study provides evidence strongly suggesting BRD1 as the causal risk gene within the locus. We show that BRD1 schizophrenia risk alleles correlate with reduced BRD1 expression and we provide direct in vitro evidence that the rs138880 risk allele lowers transcriptional drive. Moreover, we generate mice with reduced Brd1 expression and find that they display hypersensitivity to psychostimulants and behavioral abnormalities with translational relevance to schizophrenia symptomatology along with changes in neuro-chemistry and -transmission reminiscent of findings in schizophrenia. In accordance with a central role for BRD1 as a transcriptional regulator in the brain, we establish that decreased expression of Brd1 in mice leads to cerebral histone H3K14 hypo-acetylation and extensive changes in expression of genes that are enriched for schizophrenia risk and cluster in functional networks associated with mental disorders. Finally, it may be noted that neurological screenings of knockout mouse models for Creld2 and Zbed4 have not revealed phenotypes with translational relevance to schizophrenia symptomatology (38) .
Schizophrenia is a highly polygenic disorder with small effect sizes of the implicated common risk variants. The rs138880 BRD1 promoter variant contribute to schizophrenia risk with an estimated odds ratio of around 1.1 (8) , which is likely reflected in the discrete expression phenotypic effect that we observe in risk allele carriers. Hence, the Brd1 +/mouse with a ~50% reduction of Brd1 expression does not exactly reflect the effect associated with the risk allele, but rather demonstrate the molecular and functional consequences of hampered BRD1 expression.
However, despite BRD1 being very intolerant to loss of function mutations (39), a schizophrenia patient carrying a nonsense mutation in BRD1 disrupting the gene in the first exon has recently been detected in a large schizophrenia exome-sequencing study (40) , thus more directly parallelizing the Brd1 +/mouse. Furthermore, in terms of global cerebral H3 hypo-acetylationa trait that has been shown in young subjects with schizophrenia and which correlate with expression levels of genes implicated with psychiatric disorders (41) -this effect in the mice is within a clinically relevant range. Finally, by influencing histone modification and thereby the chromatin state around genes in its comprehensive schizophrenia risk enriched chromatin interactome, the presented modulation of Brd1 expression may be conceived as a way to model the highly polygenic nature of schizophrenia.
Social behavior, cognition, PCP sensitivity, and cortical neurotransmission
Negative symptoms reflect a range of deficits in normal emotional responses in individuals with schizophrenia. In mice, assessment of this domain is largely confined to tests for social interaction and general sociability. Our findings that Brd1 +/mice showed markedly different social interaction profiles and impaired ability to recall social identifiers may collectively have translational relevance to the social withdrawal (42) and social recognition deficits (43) observed in schizophrenia.
Also with translational relevance to schizophrenia symptomatology (44; 45), we observed clear deficits in associative learning in Brd1 +/mice and an accelerated time-dependent loss of acquired contextual memories. Indicative of a reduced capacity in the glutamatergic transmission to support pre-attentive processing and cognition, Brd1 +/mice displayed increased sensitivity to the disruptive effect of PCP on PPI and working memory performance.
We speculate that primarily altered neurotransmission may underlie the cognitive deficits and increased sensitivity to PCP in Brd1 +/mice. In agreement, Brd1 +/mice displayed elevated seizure propensity in response to PTZ, suggestive of increased excitability of critical neurocircuitry.
Furthermore, evaluation of sIPSCs and mIPSCs by patch-clamp recordings from pyramidal neurons demonstrated a clear deficit in inhibitory GABAergic synaptic neurotransmission in the aCC, which co-incited with a significant up-regulation of genes encoding glutamatergic receptors and a specific decrease in Pvalb immunoreactive fast-spiking interneurons in this tissue.
In support of altered cortical excitability (46) , transcriptome data revealed differential expression of DA receptor D1 (Drd1a) and disturbed DA-DARPP-32 signaling which has been linked to cognitive performance (47) , sensorimotor gating (36) , and general prefrontal dysfunction in schizophrenia cases (48) .
Psychotomimetic drug response and striatal neuro-chemistry and -signaling
Positive symptoms arise from altered striatal dopaminergic transmission (49) , and psychotic symptoms are inducible even in healthy individuals by administration of drugs that increase striatal DA activity. Similarly, sensitivity to psychostimulants is used to mimic psychosis-like behavior in mice using locomotor activity as a read-out for increased striatal DA activity.
Decreased levels of Brd1 sensitize mice to both the effect of PCP and cocaine in a manner reminiscent of the enhanced sensitivity that individuals with schizophrenia display to psychostimulant drugs (50) -but in contrast to what is observed in patients, this sensitization was not evident following amphetamine challenge. The locomotor stimulatory effect of PCP is exerted through several mechanisms aside from the direct effect of blocking NMDA receptors, including actions at DA-and 5-HT receptors (51; 52), and it has been shown to rely on DARPP-32 facilitated striatonigral signaling (53) . Amphetamine and cocaine both inhibit the reuptake of monoamines and, similar to what has been observed in individuals with schizophrenia (54), both striatal DA and 5-HT levels were significantly elevated in Brd1 +/mice. However, whereas cocaine relies on DA release to exert its effect (55) (56) (57) , amphetamine mediates its psychomotor-stimulatory effect in a firing independent way (58) . Striatal DA release is determined by DA release probability (59; 60) which is profoundly controlled by cholinergic interneurons in striatum (61) . Noteworthy, we found that two of the main cholinergic receptors, Chrna2 and Chrm4, responsible for the dynamic control of DA release probability are differentially regulated in striatal tissue of Brd1 +/mice (61)thus offering a possible explanation for the selective drug sensitivity displayed by Brd1 +/mice.
In concordance with altered DA and 5-HT transmission, transcriptome profiling of striatal tissue revealed reduced expression of both DA receptor D1 (Drd1a), D2 (Drd2) and differential expression of several 5-HT receptors. The effect of reduced Brd1 expression on the striatal transcriptome is, however, widespread and suggests dysregulation of multiple signaling pathways that ultimately appears to converge in the DARPP-32 signaling pathway of striatal medium spiny neurons (MSNs) (Figure 5B and Figure S12 ). Our finding that Creb was globally hyperphosphorylated and that its transcriptional target, c-Fos globally more abundant in the Brd1 +/mice strongly supports that DARPP-32 signaling is affected.
Enrichment of schizophrenia risk
Emphasizing the importance of BRD1 as a cardinal transcriptional regulator, we demonstrate widespread expression alterations in the brains of Brd1 +/mice. This includes altered expression of transcriptional regulators and immediate early genes (IEGs) like Homer, Bdnf, c-fos, c-jun, and Shank which have previously been linked to the etiopathology of mental disorders (62) (63) (64) . We further find that the identified DEGs are enriched for schizophrenia risk and that they cluster within known GWAS schizophrenia risk loci. In accordance with this, DEGs group in pathways that largely overlap with the recently published pathway analysis of GWAS data (65) . Thus, the identified pathways are not only centered on calcium signaling and synaptic and postsynapserelated processes but also comprise diverse immune, hormonal, and signal transduction pathwaysincluding CREB (65) .
During recent years, the hunt for schizophrenia susceptibility genes through large scale
GWASs has revealed SNPs statistically associated with the disorder but yet provided little information on their functional contribution to the pathogenesis. In general, GWAS-identified markers seem to play a major role in the regulation of gene expression rather than the alteration of protein sequence (66; 67) . We demonstrate that a risk allele in the BRD1 promoter is associated with reduced BRD1 expression, which in mice result in widespread transcriptomic changes that to a high extent affect schizophrenia risk loci and cluster in networks and pathways associated with (74) . 
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